Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoratec completes HeartMate PMA

This article was originally published in The Gray Sheet

Executive Summary

Firm submits the last module of the PMA for its HeartMate II next-generation, rotary-flow left ventricular assist system seeking approval for patients waiting for heart transplants on Dec. 22. The filing is based on data from 133 bridge-to-transplantation patients who used the device from one to 568 days. A trial is ongoing for the device as a destination therapy (1"The Gray Sheet" May 1, 2006, p. 12)...

You may also be interested in...



ACC In Brief

Thoratec's HeartMate II: Thoratec expects FDA to approve its continuous-flow left-ventricular assist device as a "bridge to transplant" in heart failure patients this summer. Results of a 133-patient pivotal trial, submitted to FDA in December, were announced at the American College of Cardiology Scientific Sessions in New Orleans March 24-27 by Leslie Miller, M.D., Georgetown University. In the trial, 75% of patients met the primary endpoint of remaining eligible for transplant for at least 180 days or completing a cardiac transplant. Compared to adverse event rates observed in the clinical trials of Thoratec's first-generation HeartMate VE, the rate of percutaneous lead infections declines 90%, stroke is down 50%, and bleeding requiring surgery is down 40%. "The safety profile is really the most important [finding]," Jeff Nelson, president of Thoratec's cardiovascular division, told "The Gray Sheet." Thoratec expects to finish a trial to support a "destination therapy" indication for HeartMate II by the middle of this year (1"The Gray Sheet" Jan. 1, 2007, In Brief)...

FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial

FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel